Description
Benlysta is an FDA-approved drug that is specifically indicated to treat and manage the symptoms of lupus. This substance is a human monoclonal antibody that is directed against the human BLyS protein so as to affect the survivability of B-cells, which are immune cells that are involved in the production of autoantibodies. Benlysta inhibits the binding of B Lymphocyte Stimulator (BLyS), a protein essential for B-cell survival, to its receptor on B-cells. By doing so, the numbers of B-cell numbers decline, and related disease activity is subsequently lowered.
